CD19-Targeting Humanized Antibody Specificity and Durability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting CD19 for B cell malignancies, such as ADC and CAR-T cell therapy, while effective, may face limitations in specificity and durability, and there is a need for more versatile and effective tools for diagnosis and treatment.
Innovation Solution
Development of a CD19-targeting humanized antibody with specific CDR regions and a multispecific antibody or chimeric antigen receptor (CAR) that can be used in various forms, including antibody conjugates and engineered immune cells, to enhance targeting and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ADC and CAR-T cell therapy are used to target CD19, then therapeutic effects are improved, but limitations in specificity and durability occur
Solution Approach 1:
The patent applies local quality by designing a humanized antibody with specifically engineered CDR regions (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, CDR-H3) that are optimized to recognize and bind to the CD19 antigen with high precision. The humanized framework regions are selectively designed to minimize immunogenicity while maintaining binding specificity, thereby improving both therapeutic effects and specificity simultaneously
Solution Approach 2:
The patent employs parameter changes by modifying the antibody structure from murine to humanized format, changing the amino acid sequences in framework regions while preserving CDR regions. This structural parameter modification reduces immunogenicity and improves durability, while the optimized CDR sequences enhance binding specificity to CD19
2Reliability
If ADC and CAR-T cell therapy are used to target CD19, then therapeutic effects are improved, but durability is reduced
Solution Approach 1:
The patent applies parameter changes by transitioning from murine to humanized antibody sequences, modifying framework region amino acids to reduce immunogenicity. This allows for prolonged circulation and sustained therapeutic effect, improving durability while maintaining the potent anti-tumor activity against CD19-expressing B cell malignancies
3Measurement precision
If humanized antibody with specific CDR regions is developed, then specificity is improved, but device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional regions: framework regions (for structural stability and reduced immunogenicity) and CDR regions (for antigen binding specificity). This modular design allows independent optimization of each region, achieving high specificity without excessive overall complexity
Solution Approach 2:
The humanized antibody framework is designed to be universally applicable while maintaining specificity through CDR regions. The framework regions provide structural support and reduced immunogenicity that can be combined with various CDR sequences, creating a versatile platform for targeting different antigens while maintaining manageable complexity
Data Source
AI summary
The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.